Lancet Infect Dis by Tapia, Milagritos D et al.
Supplementary webappendix
This webappendix formed part of the original submission and has been peer reviewed. 
We post it as supplied by the authors. 
Supplement to: Tapia MD, Sow SO, Tamboura B, et al. Maternal immunisation with 
trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a 
prospective, active-controlled, observer-blind, randomised phase 4 trial. Lancet Infect Dis 
2016; published online May 31. http://dx.doi.org/10.1016/S1473-3099(16)30054-8.
1 
 
Supplementary Webappendix 
This webappendix has been provided by authors to give the readers additional information about 
their work. 
Supplement to: Tapia MD, et al. “A prospective, active-controlled, observer-blind, 
randomized Phase 4 trial of the efficacy, safety and immunogenicity of trivalent inactivated 
influenza vaccine administered to third trimester pregnant women in Mali for the 
prevention of influenza in their infants up to 6 months of age” 
  
2 
 
“A prospective, active-controlled, observer-blind, randomized Phase 4 trial of the efficacy, 
safety and immunogenicity of trivalent inactivated influenza vaccine administered to third 
trimester pregnant women in Mali for the prevention of influenza in their infants up to 6 
months of age” 
 
Milagritos D. Tapia,M.D.,  Samba O. Sow, M.D.,  Boubou Tamboura, Pharm.D., Ibrahima 
Teguete, M.D., Marcela F. Pasetti, Ph.D., Mamoudou Kodio, Pharm.D., Uma Onwuchekwa, 
B.S., Sharon M. Tennant, Ph.D., William C. Blackwelder, Ph.D.,  Flanon Coulibaly, M.D., Awa 
Traore, Pharm.D., Adama Mamby Keita, M.D., Fadima Cheick Haidara, M.D., Fatoumata 
Diallo, M.D., Moussa Doumbia, M.D., Doh Sanogo, M.D.,  Ellen DeMatt, M.A., Nicholas H. 
Schluterman, Ph.D., Andrea Buchwald, B.S., Karen L. Kotloff, M.D., Wilbur H. Chen, M.D., 
Evan W. Orenstein, M.D., Lauren A.V. Orenstein,M.D., Julie Villanueva, Ph.D., Joseph Bresee, 
M.D., John Treanor, M.D.,  Myron M Levine M.D. 
  
3 
 
Table of Contents 
 
Study Team ................................................................................................................................................... 4 
Case Definition of Influenza-like Illness (ILI) in Infants ............................................................................. 5 
Case Definition of ILI and Severe Acute Respiratory Infection (SARI) in Women .................................... 5 
Detection of Influenza Virus, Culture and Sub-typing ................................................................................. 6 
Serologic Responses ..................................................................................................................................... 6 
Additional outcomes not included in this manuscript ................................................................................... 6 
Table S1: Time to first LCI diagnosis by vaccine timing, birthweight, and date of vaccination .................. 7 
Figure S1: The monthly distribution of 129 LCI cases recorded in infants <6 months of age during the 
entire surveillance period, categorized by virus type and by vaccine received by the mother ..................... 8 
Figure S2: Summary of 52 cases of laboratory-confirmed influenza among women observed throughout 
the study period – September 2011 to January 2014 .................................................................................... 9 
Table S2: Number of cases of influenza observed and influenza vaccine efficacy against first episodes of 
laboratory-confirmed influenza in pregnant and post-partum women .......................................................... 9 
Table S3: Geometric mean hemagglutination inhibition titers in study participants and their infants until 6 
months of age, by visit and vaccine group .................................................................................................. 10 
Table S4: Percent of study participants and their infants with HAI titers ≥40, by visit and vaccine group 11 
Table S5: Local and systemic reactogenicity observed among 4187 women who completed at least the 
first 7 days of follow up .............................................................................................................................. 12 
Table S6: Obstetrical and non-obstetrical serious adverse events observed among participating women at 
any time after vaccination until 6 months post-partum ............................................................................... 13 
Table S7: Serious adverse events (SAE) observed among infants born to participating women ............... 14 
Table S8: Timing and causes of death observed among the 89 infant deaths ............................................. 15 
Table S9: Ballard score and birth weight analysis among infants born to women vaccinated with either 
TIIV or MCV and born in the influenza season .......................................................................................... 16 
References ................................................................................................................................................... 17 
 
  
4 
 
Study Team 
 
CVD-Mali 
Clinical Team: Fadima Cheick Haidara, Fatoumata Diallo, Moussa Doumbia, Flanon Coulibaly, Ibrahima Tegueté, 
Doh Sanogo, Adama Mamby Keita, Evan Orenstein, Lauren Orenstein, Sidiki Koné, Bintou A. Tangara, Bréhima 
Diarra, Djeneba Traoré, Drissa Diarra, Abdoulaye Sidibé, Sékou Doumbia, Yacouba Diarra, Oumar Diakité, Sidi 
Diakité, Boubacar Bathily, Sibiry Samaté, Mamadou T. Keita, Yiriba Diarra, Aminata Traoré, Daouda Koné, 
Mariétou Samaké, Mama Camara, Awa Traoré, Moussa Sanogo, Oumar Mariko, Fatoumata Traoré, Aboubacar 
Samaké, Amadou Sagara, Fatoumata Maiga, Safiatou Coulibaly, Aissata Diarra, Tiècoura Bocoum, Balla Traoré, 
Karime Bayoko, Nana Gassama, Adama Diakité, Adama Coulibaly, Youssouf Diakité, Famakan Diango, Sinaly 
Dembele, Alassane Sangaré, Mama Mounkoro, Diakaridia Sidibé, Souleymane Diakité, Modibo Soumaré 
Pharmacy Team: Mamoudou Kodio and Sekou Keita 
Informatics and Support: Uma Onwuchekwa, Oualy Diawara, Moussa Traoré, Kounandji Diarra, Mahamane 
Djiteye, Ballan Sangaré 
Laboratory Team: Boubou Tamboura, Awa Traoré, Abdoulaye Sangaré, Chaka Dit Tiédié Diallo, Aliou Touré, 
Oumarou A. Traore 
 
CVD- University of Maryland 
Laboratory Team: Mardi Reymann, Ifayet Mayo, Deanna Toema, Sofie Livio, Sunil Sen 
 
 
 
  
5 
 
Case Definition of Influenza-like Illness (ILI) in Infants 
 
Either of the 2 following conditions reported by the caretaker or observed by a clinician: 
 Fever without an apparent source, documented by a clinician’s measurement to be an axillary temperature >38°C 
or maternal perception of fever and administration of antipyretic in previous 8 hours 
* No source means that there is no apparent cause for the fever such as soft tissue infection, although 
generalized symptoms such as irritability, loss of appetite, and/or lethargy may be present;  
OR 
 Fever (as defined below)* plus acute respiratory infection.  
Acute respiratory infection is defined as ANY of the following on the same or consecutive days:  runny nose, 
nasal congestion, cough, difficulty breathing, pus draining from ear or wheezing; 
    PLUS 
 > 7 days after last reported fever 
Fever was defined as any of the following: 
 Mother’s perception that the infant had fever during the previous 24 hours 
 Mother measured the infant’s temperature as >38oC during the previous 24 hours 
 Clinician or study staff measure the infant’s temperature to be >38oC 
 Maternal perception of fever and administration of antipyretic in previous 8 hours 
Case Definition of ILI and Severe Acute Respiratory Infection (SARI) in Women 
Women met ILI criteria if the following were observed by the examining physician or were part of clinical history: 
 Onset of fever (oral temperature >38oC) < 7 days duration AND 
 Cough or sore throat AND  
 Absence of other diagnoses 
OR 
 Onset of feverish feeling < 7 days duration AND 
 Cough or sore throat or chest pain on breathing in AND  
 Absence of other diagnoses 
 
Women met SARI criteria if the following were observed by the examining physician or were part of clinical 
history: 
 Sudden onset of fever over 38oC or perception of fever and self-administration of antipyretic in the previous 8 
hours AND 
 Cough or sore throat AND 
 Shortness of breath or difficulty breathing 
 Patient may or may not be hospitalized 
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Detection of Influenza Virus, Culture and Sub-typing  
Using an ABI 7500 RT-PCR machine, RT-PCR kits from the Centers for Disease Control (CDC) were used 
to detect pandemic swine influenza, “seasonal” influenza A H3N2, “human” (pre-2009) H1N1 viruses and influenza 
B viruses. RNA extraction was performed following the recommended CDC method (QIAamp® viral RNA kit). 
RNA was tested immediately with the CDC real time RT-PCR protocol for detection and characterization of swine 
influenza. Analysis of data was performed using the software supplied with the Applied Biosystems™ real time 
PCR system ABI7500. Test runs in which positive and/or negative controls did not give the proper result were 
invalidated and the run was repeated. Positive samples were sent for viral culture and antigenic sub-typing according 
to standard methods.1  
Serologic Responses 
Seed viruses matching the vaccine strains were provided by the CDC Influenza Branch, and virus stocks 
were produced in embryonated hens’ eggs, as described.2  Hemagglutination inhibition (HAI) antibody titers to 
specific vaccine components were measured by incubating serially-diluted serum samples (starting at 1:4) with 4 
HA Units of each antigen and chicken erythrocytes, following standard techniques.3 Sera were pre-treated with 
receptor destroying enzyme (Denka Seiken Co. Tokyo, Japan) to inactivate nonspecific inhibitors of viral 
hemagglutination.4 HAI titers are calculated as the inverse of the highest dilution that inhibits hemagglutination. 
Additional outcomes not included in this manuscript 
An additional secondary outcome that will be presented in another paper includes the levels of maternal 
meningococcal antibodies (A, C, Y and W-135) measured by serum bactericidal assay, before and 4 weeks after 
vaccination, at delivery and 3 and 6 months after delivery. Additional tertiary outcomes that will be presented in 
another paper include: i) the occurrence of LCI among household contacts < 5 years of age; ii) the levels of 
maternally-derived serogroup-specific serum bactericidal antibodies (A, C, Y & W-135) at birth and 3 and 6 months 
of age; iii) the frequency of positive influenza by RT-PCR among samples collected from healthy infants aged 3 and 
6 months (data are not yet analyzed); iv) the occurrence of pneumonia (as defined by the World Health 
Organization) in infants up to 6 months of age (data are not yet analyzed); v) the occurrence of meningococcal 
disease due to each of the vaccine serogroups (A, C, Y, W-135) in infants up to 6 months of age; vi) the cost of LCI 
and ILI in infants up to 6 months of age; vii) the cost of LCI and ILI in women 
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Table S1: Time to first LCI diagnosis by vaccine timing, birthweight, and date of vaccination 
 
 Number of live-born 
babies 
Number with LCI 
(%) 
p-value 
(chi-
square) 
Hazard 
ratioh 
95% 
Confidence 
interval 
p-value 
(hazard 
ratio) 
Vaccine 
   MCV 
   TIIV 
 
2041 
2064 
 
77 (3·8%) 
52 (2.5%) 
 
0·02 
 
Ref. 
0·67 
 
 
0·51-0·86 
 
 
0·002 
Time from TIIV to DeliveryTIIV 
   0-14 days 
   15+ days 
 
 
201 
1862 
 
 
8 (4·0%) 
44 (2.4%) 
 
 
0·17 
 
 
Ref. 
0·52 
 
 
 
0·31-0·90 
 
 
 
0·02 
Birth weightTIIV 
   <2500 g 
   2500+ g 
   Per 1000g increase* 
 
191 
1869 
N/A 
 
4 (2·1%) 
48 (2·6%) 
N/A 
 
1f 
 
Ref. 
1·07 
1·21 
 
 
0·52-2·21 
0·79-1·87 
 
 
0·85 
0·38 
Birth weightMCV 
   <2500 g 
   2500+ g 
   Per 1000g increase** 
 
167 
1871 
N/A 
 
7 (4·2%) 
70 (3·7%) 
N/A 
 
0·68f 
 
Ref. 
0·81 
1·04 
 
 
0·46-1·41 
0·72-1·50 
 
 
0·46 
0·84 
Date of vaccinationTIIV 
   Sep 2011-July 2012 
   Aug 2012-Apr 2013 
 
1117 
946 
 
29 (2·6%) 
23 (2·4%) 
 
0·81 
 
Ref. 
1·21 
 
 
0·80-1·84 
 
 
0·36 
Date of vaccination 
Interaction between date of vaccination 
and vaccine group 
 
N/A 
 
N/A 
  
 
1·41 
 
 
0·84-2·36 
 
 
0·19 
fFisher’s exact test. Other p-values in this column are from Pearson’s chi-square test. 
TIIVAmong participants whose mothers were randomized to receive the influenza vaccine. 
MCVAmong participants whose mothers were randomized to receive the meningitis vaccine. 
hLog-rank test, unadjusted for other variables 
cCox regression model with terms for vaccine assignment (not shown in table), date of vaccination (not shown in 
table), and interaction term between these two terms (shown in table) 
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Figure S1: The monthly distribution of 129 LCI cases recorded in infants <6 months of age during the entire 
surveillance period, categorized by virus type and by vaccine received by the mother 
 
 
 
Panel A - A/California/7/2009(H1N1[pandemic]-like), A/Perth/16/2009(H3N2)-like and B/Brisbane/60/2008-like 
administered to pregnant women from September 2011-October 2012  
Panel B - A/California/7/2009(H1N1[pandemic]-like), A/Victoria/361/2011(H3N2)-like and B/Wisconsin/1/2010-
like administered to pregnant women from December 2012-April 2013  
Panel C - Quadrivalent meningococcal conjugate vaccine administered to pregnant women September 2011-April 
2013 
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Figure S2: Summary of 52 cases of laboratory-confirmed influenza among women observed throughout the 
study period – September 2011 to January 2014 
 
 
*Indicates that 1 of the 2 women who had LCI in February 2013 was randomized when Formulation 1 of TIIV was 
available and the other when Formulation 2 was available. 
Figure S2 represents a summary of the 52 LCI cases that occurred among women in both vaccine groups over the 
entire surveillance period. Cases are classified according to influenza type. The bar at the top indicates the 
formulation of influenza vaccine that was available during the time that the women who experienced LCI were 
vaccinated. As of January 2013, all but one of the women who had LCI had been randomized when Formulation 2 
was available. 
Table S2: Number of cases, incidence and influenza vaccine efficacy against first episodes of laboratory-
confirmed influenza in pregnant and post-partum women  
 
 TIIV 
N = 2108 
MCV 
N = 2085 Vaccine 
Efficacy 
(95% CI) 
Period Number of 
LCI cases 
Incidence 
(per 1000 
weeks 
observation) 
Number of 
LCI cases 
Incidence 
(per 1000 
weeks 
observation) 
Pregnancy 4 0·30 17 1·30 76·6% 
(28·4 – 94·3) 
Post-partum 7 0·17 23 0·58 70·1% 
(28·0 – 89·1) 
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Table S3: Geometric mean hemagglutination inhibition titers in study participants and their infants until 6 
months of age, by visit and vaccine group 
 TIIV MCV 
p-valuet 
Mothers n GMT 95% CI n GMT 95% CI 
Baseline 104 20·9 16·5 26·5 76 17·4 13·0 23·2 0·32 
28 days post vaccination 88 311·7 231·0 420·6 58 17·6 13·0 23·9 <0·0001 
Delivery 96 183·7 135·0 249·8 68 18·3 13·5 24·7 <0·0001 
3 months after delivery 71 154·1 111·1 213·7 45 27·9 18·6 41·8 <0·0001 
6 months after delivery 66 157·9 112·8 221·2 46 39·5 26·3 59·4 <0·0001 
Infants          
Birth 96 141··6 102·6 195·4 67 17·2 12·8 23·1 <0·0001 
3 months of age 70 39·0 29·5 51·5 45 12·1 8·3 17·6 <0·0001 
6 months of age 67 33··7 24·8 45·7 46 18·3 10·9 30·7 0·03 
tStudent’s t-test, comparing log2-tranformed mean HAI titers between vaccine groups. 
GMT: geometric mean titer.  
CI: confidence interval. 
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Table S4: Percent of study participants and their infants with HAI titers ≥40, by visit and vaccine group 
 
 TIIV MCV 
p-valuex 
 n ≥40 n % ≥40 n  ≥40 n % ≥40 
Baseline 27 104 26% 19 76 25% 0·88 
28 days post vaccination 82 88 93% 14 58 24% <0·0001 
Delivery 83 96 86% 19 68 28% <0·0001 
3 months after delivery 60 71 85% 16 45 36% <0·0001 
6 months after delivery 53 66 80% 22 46 48% <0·0001 
Infants        
Birth 76 96 79% 19 67 28% <0·0001 
3 months of age 29 70 41% 7 45 16% 0·004 
6 months of age 30 67 45% 13 46 28% 0·08 
xPearson’s chi-square test, comparing proportion of HAI titers >40 between vaccine groups. 
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Table S5: Local and systemic reactogenicity observed among 4187 women who completed at least the first 7 
days of follow up 
 
  TIIV 
N = 2105 
MCV 
N = 2082 
p-value 
 Severity N (%) N (%)  
Local Reactogenicity 
Pain Mild  126 (3·0%)  228 (5·47%) <0·0001 
 Moderate  5 (0·12%)  23 (0·55%) <0·0001 
 Severe  1 (0·02%)  2 (0·05%) 1 
Redness Mild  6 (0·14%) 11 (0·26%) 0·23 
 Moderate  0 (0·%0)  0 (0·0%) 1 
 Severe  0 (0·0%)  1 (0·0%) 1 
Swelling Mild  12 (0·29%)  31 (0·74%) 0·003 
 Moderate  1 (0·0%2)  2 (0·05%) 1 
 Severe  0 (0·0%)  1 (0·02%) 1 
>  1 local reaction 140 (6·65%) 258 (12·4%) <0·0001 
Systemic Reactogenicity 
Fatigue Mild 8 (0·19%) 17 (0·4%1) 0·07 
 Moderate 1 (0·02%) 1 (0·02%) 1 
 Severe 0 (0·0%) 0 (0·0%) 1 
Febrile sensation Mild 41 (0·98%) 53 (1·27%) 0·21 
 Moderate 1 (0·02%) 3 (0·07%) 0·37 
 Severe 1 (0·02%) 0 (0·0%) 1 
Headache Mild 34 (0·82%) 46 (1·1%) 0·18 
 Moderate 4 (0·10%) 4 (0·1%) 1 
 Severe 1 (0·02%) 0 (0·0%) 1 
Myalgia Mild 4 (0·10%) 16 (0·38%) 0·007 
 Moderate 1 (0·02%) 2 (0·05%) 0·62 
 Severe 0 (0·0%) 0 (0·0%) 1 
>  1 systemic reaction 73 (3·47%) 113 (5·43%) 0·002 
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Table S6: Obstetrical and non-obstetrical serious adverse events observed among participating women at any 
time after vaccination until 6 months post-partum 
 
Event 
TIIV 
N = 2108 
MCV 
N = 2085 p-value 
N (%) N (%) 
Gestational hypertension 4 (0·2%) 2 (0·1%) 0·69 
Pre-eclampsia 26 (1·2%) 24 (1·2%) 0·89 
Eclampsia 1 (0·1%) 6* (0·3%) 0·07 
Chorioamnionitis 2 (0·1%) 1 (0·1%) 1 
Premature rupture of membranes 3 (0·1%) 4 (0·2%) 1 
Placenta previa 3 (0·1%) 6 (0·3%) 0·34 
Placental abruption 6 (0·3%) 4 (0·2%) 0·75 
Uterine rupture 2 (0·1%) 2 (0·1%) 1 
Post-partum hemorrhage 2 (0·1%) 3 (0·1%) 1 
Separation of pubic symphysis 1 (0·1%) 0 (0%) 1 
HIV infection diagnosed post-vaccination** 1 (0·1%) 6 (0·3%) 1 
Serious infection in pregnancy# 9 (0·4%) 3 (0·1%) 0·07 
Peritonitis 1* (0·1%) 0 (0) 1 
Events unrelated to pregnancy (occurred > 42 days post-partum) 
Cardiomyopathy 1 (0·1) 1 (0·1) 1 
Fracture of right leg 1 (0·1) 0 (0) 1 
Difficulty walking 0 (0) 1 (0·1) 1 
Extra-pulmonary tuberculosis 0 (0) 1 (0·1) 1 
Cervical fracture post trauma 0 (0) 1* (0·1) 1 
Electrocution 0 (0) 1* (0·1) 1 
Sudden death, likely of cardiac origin 1* (0·1) 0 (0%) 1 
* 1 fatal case included. 
** These diagnoses were unknown to the participant prior to enrollment. 
# These episodes include cases of hospitalized malaria (7), respiratory infections (2), 
pyelonephritis (2) and unspecified post-partum infection (1). 
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Table S7: Serious adverse events (SAE) observed among infants born to participating women 
 
Event§ 
TIIV 
N = 2064* 
MCV 
N = 2041* P-value 
N (%)# N (%)# 
Stillbirth 24 (1·2%)** 30 (1·5%) 0·41 
Major congenital malformation 6 (0·3%) 4 (0·2%) 0·75 
Meconium aspiration syndrome 1 (0·1%) 1 (0·1%) 1 
Presumed/ Neonatal infection 60 (2·9%) 37 (1·8%) 0·02 
Perinatal asphyxia 26 (1·3%) 20 (1·0%) 0·46 
Respiratory infection 29 (1·4%) 20 (1·0%) 0·25 
Malaria 4 (0·2%) 3 (0·1%) 1 
Meningitis (including 3 pneumococcal) 2 (0·1%) 4 (0·2%) 0·45 
Low birthweight/ Small for gestational age 5 (0·2%) 7 (0·3%) 0·58 
Gastrointestinal infection 3 (0·1%) 2 (0·1%) 1 
Unspecified infection 2 (0·1%) 1 (0·1%) 1 
Microbiologically-confirmed bacteremia 2 (0·1%) 1 (0·1%) 1 
Abdominal distension/ obstruction 1 (0·1%) 4 (0·2%) 0·22 
Sudden infant death syndrome 2 (0·1%) 2 (0·1%) 1 
Other 6 (0·2%) 2 (0·1%) 0·29 
Infant deaths 52 (2·5%) 37 (1·8%) 0·13 
§ Events are not mutually exclusive. 
* Number of livebirths per vaccine group. 
** Stillbirth rate is calculated among all births. 
# Percentage of live births except where indicated otherwise. 
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Table S8: Timing and causes of death observed among the 89 infant deaths 
 
Category of event TIIV 
N = 52 
MCV 
N = 37 
Age of death <7days 7-28 days >28 days <7days 7-28 days >28 days 
Congenital anomaly 2 0 2 2 1 0 
Infection* 4 1 12 3 5 6 
Perinatal asphyxia or meconium aspiration 
syndrome 
17 0 0 12 0 0 
Prematurity 6 2 0 5 0 0 
Other 0 2 1 0 0 1 
Unknown 0 1 2 1 0 1 
This category includes 4 episodes of gastroenteritis, 3 of malaria, 3 of meningitis, 11 of unknown neonatal infection, 
1 of oral candidiasis, 8 of pneumonia and 1 of pseudomonas bacteremia. 
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Table S9: Ballard score and birth weight analysis among infants born to women vaccinated with either TIIV 
or MCV and born in the influenza season 
 
Preterm infant, by vaccine 
assignment Total TIIV MCV P-value 
Correlation 
with Ballard** 
Ultrasound in first trimester, available 
for 551 participants 67/551 (12·2%) 30/271 (11·1%) 37/280 (13·2%) 0·44 0·41 
Date of last menstrual period, 
available for 207 participants 32/207 (15·5%) 17/109 (15·6%) 15/98 (15·3%) 0·95 0·23 
 
Birthweight of infants, at time of  live birth, by vaccine 
assignment Total 
TIIV 
N = 2063 
MCV 
N = 2041 
P-value** 
Low birthweight (<2500 g) 
    All live births 
    Births during peak influenza season* 
 
357 (8·7%) 
167 (8·9%) 
 
191 (9·3%) 
90 (9·6%) 
 
166 (8·2%) 
77 (8·2%) 
 
0·20 
0·29 
Birthweight – mean g (SD) 
    All live births 
    Births during peak influenza season* 
 
3016 (458) 
3007 (460) 
 
3017 (472) 
3013 (483) 
 
3015 (444) 
3002 (437) 
 
0·91 
0·61 
 
Birthweight of infants, at time of  live birth, by vaccine 
timing and assignment Total 
Time from vaccination to delivery  
0-14 days 15+ days P-value*** 
Birthweight – mean g (SD) 
    Assigned to TIIV 
 
    Assigned to MCV 
 
3017 (472) 
 
3015 (444) 
 
2918 (496) 
[N=201] 
2948 (449) 
[N=188] 
 
3027 (468) 
[N=1862] 
3022 (443) 
[N=1852] 
 
0·002 
 
0·03 
* Peak influenza season was September 1-October 31 and February 1-April 30 (n=942 infants in TIIV group and 942 infants in MCV group) 
**p-values comparing birthweights between TIIV and MCV groups, by Student’s t-tests. 
***p-values comparing birthweights within each vaccine group between infants whose mothers were vaccinated 0-14 and 15+ days before delivery, 
by Student’s t-tests. 
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